Author Archives: Inês Martins PhD

Rituximab Trial for Systemic Sclerosis-associated PAH Enrolling Participants

The National Institute of Allergy and Infectious Diseases is recruiting patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) to assess if Rituxan (rituximab) immunotherapy is effective against disease progression. The randomized Phase 2 study, titled “Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH),” is enrolling patients…

Scleroderma Patients with PAH Seen to Benefit from PDE-5 Inhibitors as Early Therapy

People with systemic sclerosis-associated pulmonary arterial hypertension (SS-PAH) were seen to have a significantly worse prognosis when treated with an endothelin receptor antagonist (ERA), compared to those treated with a phosphodiesterase-5 (PDE-5) inhibitor or with a combination of an ERA/PDE-5 inhibitor. The study, “Association Between Initial Oral Therapy and Outcomes…

Implanted Heart Monitor in Systemic Sclerosis Patients Helps Detect Arrhythmias Early

Keeping close watch over systemic sclerosis patients, at high risk for cardiovascular disease, with an implanted heart monitoring device may allow for early detection and treatment of cardiac events. Researchers at the University of Leeds, in the United Kingdom, revealed the potential of an implantable loop recorder for detecting abnormalities that affect the heart’s electrical…